DANESSA COLES: Open Payments
NPI 1013625086 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,666 in 60 payments from 24 companies in 2025. Trend: 2023 $4,339 · 2024 $2,715 · 2025 $1,666
Food & beverage: $1,337Education: $329
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 6 | $243 |
| Alexion Pharmaceuticals, Inc. | 5 | $156 |
| Novartis Pharmaceuticals Corporation | 6 | $140 |
| Astellas Pharma US Inc | 4 | $122 |
| Merck Sharp & Dohme LLC | 4 | $117 |
| E.R. Squibb & Sons, L.L.C. | 5 | $104 |
| SANOFI-AVENTIS U.S. LLC | 1 | $91 |
| Myriad Genetic Laboratories, Inc. | 3 | $74 |
| TAIHO ONCOLOGY, INC. | 3 | $73 |
| GENZYME CORPORATION | 2 | $65 |
Products named: ULTOMIRIS, SARCLISA, KEYTRUDA, OPDIVO, TECVAYLI, ERLEADA, DARZALEX, MYRISK.
Industry payments across CA — which companies pay providers there.
